Business Standard
Monday, Nov 23, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Sun Pharma unit gets USFDA nod for anti-allergic drug
Press Trust of India / Mumbai November 6, 2009, 19:04 IST

Drug firm Sun Pharma today said it has received the US regulator's approval for the generic version of Acular, used to treat pain and swelling after eye surgeries.

BSE | NSE
Price  
 
 
Related Stories
News Now
-Caraco looking at shifting production to India
-Sun Pharma accuses Taro director of misusing funds
-Sun Pharma net profit dips 11.5%
-'We are not a topline-driven company'
-Sun Pharma profit dips 11.49%
-Bhupesh Bhandari: The new pharmaceutical order

The US Food and Drug Administrator (USFDA) has granted approval for the Abbreviated New Drug Application (ANDA) for the generic version of Acular, which is also known as Ketotrolac Tromethamine Opthalmic Solution, Sun Pharma said in a filing to the Bombay Stock Exchange.

US-based drug firm Allergan Inc has patent rights over Ketotrolac Tromethamine Opthalmic Solution and the company is selling the drug under the brand Acular.

The drug is indicated for the temporary relief of ocular itching due to seasonal allergic conductivities, it said.

Arrow Other Stories     
- Sensex makes remarkable recovery, regains 17K
- L N Mittal doubles his stake in Ophir Energy
- Indian handicraft firms to participate in Munich fair
- Microsoft eyes Indian smartphone mkt
- RIL Hazira unit bags 'Excellent Energy Efficient Unit Award'
More  
  Read Business news in 
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
Share this Story  
 
 
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Indian CIOs more progressive than global counterparts: IBM study
- Obama-Singh to run last mile on nuclear deal
- IAF orders more Tejas LCAs to replace MiG-21s
- Ubuntu 9.10: A karmic disconnection
- L N Mittal doubles his stake in Ophir Energy
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should sugar prices be decontrolled?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback